BC Week In Review | Jun 23, 2014
Clinical News

Combo Dual Therapy Stent: Phase IV started

OrbusNeich said investigators began the open-label, international Phase IV REDUCE trial to compare the 3-month Combo Dual Therapy Stent vs. the standard 12-month Combo Dual Therapy Stent in about 1,500 patients with ACS. The Combo...
BC Week In Review | Apr 7, 2014
Clinical News

Combo Dual Therapy Stent: Completed postmarketing study enrollment

OrbusNeich completed enrollment of 1,000 patients in the European REMEDEE Registry study to evaluate the Combo Dual Therapy Stent with a clinical follow up of up to 5 years. The Combo Dual Therapy Stent, which...
BC Week In Review | Mar 3, 2014
Clinical News

Combo Dual Therapy Stent: Pivotal trial started

OrbusNeich began the single-blind, U.S. and Japanese pivotal HARMONEE trial to compare its Combo Dual Therapy Stent vs. an everolimus-eluting stent in 572 patients with ischemic coronary disease and NSTEMI. The trial comprises 3 cohorts....
BC Week In Review | Apr 29, 2013
Clinical News

Combo Bio-engineered Sirolimus Eluting Stent: Pivotal trial data

The open-label, Australian pivotal REMEDEE trial in 183 patients with de novo native coronary artery stenosis showed that OrbusNeich's Combo Bio-engineered Sirolimus Eluting stent met the primary endpoint of non-inferiority to the Taxus Liberte paclitaxel-eluting...
BC Week In Review | Oct 11, 2010
Clinical News

Combo Bio-engineered Sirolimus Eluting Stent: Completed Phase II enrollment

OrbusNeich completed enrollment of 183 patients in the open-label, international Phase II REMEDEE trial to compare its Combo Bio-engineered stent vs. Taxus Liberte paclitaxel-eluting stent from Boston Scientific Corp. (NYSE:BSX, Natick, Mass.). OrbusNeich's stent utilizes...
BC Week In Review | Dec 14, 2009
Clinical News

Combo Bio-engineered Sirolimus Eluting Stent: Phase II started

OrbusNeich began the open-label, international Phase II REMEDEE trial in 180 patients to compare its Combo Bio-engineered stent vs. Taxus Liberte paclitaxel-eluting stent from Boston Scientific Corp. (NYSE:BSX, Natick, Mass.). OrbusNeich's stent utilizes the SynBiosys...
BC Week In Review | Oct 5, 2009
Clinical News

OrbusNeich preclinical data

In porcine models of CAD, the Combo Bio-engineered Sirolimus Eluting Stent had endothelial coverage and functionality similar to OrbusNeich 's marketed Genous Bio-engineered R stent at 14 days. Additionally, the Combo Stent had a 50%...
Items per page:
1 - 7 of 7